파브리병 시장 보고서 : 유형별, 진단 및 치료별, 최종 사용자별, 지역별(2026-2034년)

The global fabry disease market size reached USD 2.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.78% during 2026-2034. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

This report provides an analysis of the key trends in each segment of the global fabry disease market, along with forecasts at the global, regional, and country level from 2026-2034. The report has categorized the market based on type, diagnosis and treatment, and end user.

Type Insights:

• Type 1
• Type 2
• Others

The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

• Diagnosis
• Blood Test
• Genetic Test
• Parenteral Test
• Others
• Treatment
• Enzyme Replacement Therapy
• Oral Therapy
• Adjunct Therapy
• Others

End User Insights:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global fabry disease market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global fabry disease market?
• What are the key regional markets?
• Which countries represent the most attractive fabry disease markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the diagnosis and treatment?
• What is the breakup of the market based on the end user?
• What is the competitive structure of the global fabry disease market?
• Who are the key players/companies in the global fabry disease market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Fabry Disease Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Type 1
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Type 2
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

• 7.1 Diagnosis
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Blood Test
    • 7.1.2.2 Genetic Test
    • 7.1.2.3 Parenteral Test
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Treatment
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Enzyme Replacement Therapy
    • 7.2.2.2 Oral Therapy
    • 7.2.2.3 Adjunct Therapy
    • 7.2.2.4 Others
  • 7.2.3 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Homecare
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Specialty Clinics
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Amicus Therapeutics
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Freeline
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Idorsia Pharmaceuticals Ltd
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 JCR Pharmaceuticals Co. Ltd
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Protalix BioTherapeutics
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Sangamo Therapeutics Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis